Entering text into the input field will update the search result below

Mid-stage study underway for Can-Fite's NASH candidate namodenoson

Nov. 27, 2017 11:55 AM ETCan-Fite BioPharma Ltd. (CANF) StockCANFBy: Douglas W. House, SA News Editor1 Comment
  • The first patient has been enrolled in a 60-subject Phase 2 clinical trial assessing Can-Fite BioPharma's (CANF -2.1%) Namodenoson for the treatment of nonalcoholic fatty liver disease with/without nonalcoholic steatohepatitis.
  • The primary endpoints of the 12-week study are safety and the percent change from baseline in liver fat (triglyceride) concentration.
  • Namodenoson, formerly CF102, is an orally available small molecule that binds to the A3 adenosine receptor. It is also being developed for second-line liver cancer.
  • Previously: Can-Fite on go with mid-stage study of namodenoson in fatty liver disease (July 17)

Recommended For You

About CANF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CANF--
Can-Fite BioPharma Ltd.